Compounded Semaglutide After the Shortage: FDA Enforcement and Switch Options
FDA resolved the semaglutide shortage on February 21, 2025. Temporary shortage-based enforcement discretion ended after an April 24 court decision for 503A pharmacies and on May 22 for 503B facilities.
This guide separates those dates from FDA's pending 503B bulk-list proposal and compares paths to discuss with a prescriber.
By GLP-1 Picks, an independent comparison publication. Sources linked below. Our editorial policy.
Summarize this article with

In this article
- 01What Happened: The FDA Crackdown Timeline
- 02Is Any Compounded Semaglutide Still Legal?
- 03Your 4 Options as a Former Compounded Semaglutide Patient
- 04Option 1: Discuss Compounded Tirzepatide With Your Prescriber
- 05Option 2: Brand-Name Wegovy with Manufacturer Savings
- 06Option 3: Foundayo (Oral Orforglipron), The Pill Alternative
- 07Option 4: Appeal Your Insurance Denial
- 08How to Choose Between Your Options
- 09What This Means for Semaglutide vs. Tirzepatide
- 10Frequently Asked Questions
- 11Sources
FDA resolved the semaglutide shortage on February 21, 2025. Its shortage-related enforcement discretion for 503A semaglutide injection compounding ended after the April 24, 2025 court decision; the 503B period ran through May 22, 2025.
FDA's dated policy log records both transitions.
Those dates ended a broad shortage pathway; they did not create a one-sentence federal ban on every patient-specific compounded prescription.
A particular preparation must satisfy the applicable section 503A or 503B and state-law conditions, including restrictions on products that are essentially copies of commercially available drugs.
On March 3, 2026, FDA announced warning letters to 30 telehealth companies over marketing that presented compounded GLP-1 products as approved, generic, identical, or clinically equivalent to approved brands.
That agency-wide announcement is broader than our non-exhaustive provider tracker and does not mean every letter alleged an unsafe medication.
Separately, FDA's April 30 proposal would exclude semaglutide, tirzepatide, and liraglutide from the 503B bulk drug substances list.
The comment period closed July 30, 2026; a closed comment period does not make a proposed rule final.
See the FDA's concerns about unapproved GLP-1 drugs and our 503B proposal guide.
One program we track, MEDVi, received letter 721455 on February 20, 2026, over marketing claims rather than any finding about the medication itself; the review carries its price and service record, and the safety checker the letter.
Quick answer: paths to discuss with your prescriber:
- •Ask whether a patient-specific compounded preparation is appropriate: Compare EverPrime compounded tirzepatide plans and Shed advertises $299/mo. Availability and price do not establish that a specific prescription satisfies 503A/503B and state-law conditions; see the compounded tirzepatide guide
- •Switch to brand-name Wegovy: NovoCare lists the pen at $199/mo for the first two low-dose fills, then $349/mo at standard strengths ($399 HD), and pill from $149/mo, or as little as $25/mo for eligible commercially insured patients under the savings-card terms. Hers lists pill medication from $149 or pen from $199 plus required $39 first-month/$149 ongoing membership.
- •Switch to brand-name Zepbound: LillyDirect $299/mo starter vial, a prescription option to discuss with your clinician. Sprout's tirzepatide plan at $199 every 4 weeks (2025 FDA warning for misleading compounded-drug marketing) is compounded, not Zepbound; current branded availability is not confirmed.
- •Try an oral pill: Foundayo (orforglipron) starts at $149/mo at 0.8 mg and rises by dose/refill timing; it requires no injection or fasting. The Wegovy pill starts at $149/mo through NovoCare and may cost as little as $25/mo for eligible commercially insured patients. Compare all oral GLP-1 pills →
- •Ask about a patient-specific semaglutide formulation: EverPrime lists semaglutide prices by commitment and membership. Confirm the dispensing pharmacy, exact formulation, legal basis, and ongoing price; 503A pharmacies are state-licensed, not FDA-registered
This guide covers the sourced FDA timeline, product-safety concerns reported by the agency, and public records you can review in our warning and transparency checker.
The checker is not an exhaustive FDA database and cannot verify a provider's compliance or certify a medication as safe. For the legal framework, see the brand vs compounded guide.
Check the rules before you choose a program
Ask any program which medication you'd get, which pharmacy makes it and who writes the prescription. The FDA alerts page shows what has changed.
Read FDA alerts and compounding updates →What Happened: The FDA Crackdown Timeline
The legal status of compounded GLP-1 medications changed significantly over the past 18 months. Here is the timeline of how it unfolded:
| Date | Event |
|---|---|
| Feb 21, 2025 | FDA determined the semaglutide injection shortage was resolved |
| Apr 24, 2025 | A federal district court decided a preliminary-injunction request, ending FDA's temporary enforcement-discretion period for state-licensed 503A pharmacies making shortage-based copies (FDA had extended it from April 22 to the later of that date or the ruling) |
| May 22, 2025 | FDA's temporary enforcement-discretion period ended for 503B outsourcing facilities making shortage-based copies |
| May, Sep 2025 | FDA issued warning letters to compounding pharmacies that continued operations, including JulyMD (September 2025) |
| Late 2025 | Court challenges from pharmacy groups temporarily complicated enforcement but did not overturn FDA authority |
| Mar 3, 2026 | FDA announced 30 warning letters to telehealth companies over marketing of compounded GLP-1 products. The announcement addressed promotional claims; it did not state that every cited medication was unsafe. |
| Apr 30, 2026 | FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. The public comment period, extended under Docket FDA-2018-N-3240, closed July 30, 2026. The proposal is not a final rule. |
| Feb 6, 2026 (delayed public disclosure Jun 2026) | HHS General Counsel referred Hims & Hers Health to the Department of Justice for compounding violations, the most significant telehealth enforcement escalation to date. |
| Jul 30, 2026 (extended from Jun 29) | Public comments closed on FDA's 503B bulk-list proposal. Closing comments is a procedural milestone, not finalization of the proposal. |
FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulk drug substances list when they are compounded from bulk substances under that pathway.
The proposal must be distinguished from the separate drug-shortage pathway and from patient-specific 503A rules.
Comments closed July 30, 2026, but FDA has not set a finalization date in the cited notice; do not treat the proposal as current final law.
The core change is narrower: shortage status had supported temporary enforcement discretion for certain copies under FDA policy. Once FDA resolved the semaglutide shortage, that shortage route and its transition periods ended.
Other section 503A or 503B conditions still require a fact-specific analysis; the shortage decision alone does not answer every compounding scenario.
Is Any Compounded Semaglutide Still Legal?
The answer depends on the specific prescription, pharmacy, substance, and applicable federal and state rules.
Section 503A can apply to patient-specific prescriptions, but it has multiple conditions, including limits on products that are essentially copies of commercially available drugs.
A prescriber-documented determination that a compounded version produces a significant difference for an identified patient can be relevant; it is not an automatic exemption from every other requirement.
- •Patient-specific prescription, Section 503A generally requires compounding for an identified individual patient under a valid prescription or the statute's limited anticipatory-compounding conditions.
- •Essentially-a-copy analysis, When a commercially available drug exists, the prescriber should document any patient-specific significant difference rather than relying on a generic claim such as lower price or convenience.
- •All other conditions, Ingredient eligibility, pharmacy practice, labeling, state law, and other statutory conditions still apply. Section 503B uses a separate framework and FDA registration does not approve a compounded product.
Do not infer compliance from a provider's claim that a product is customized, from a low advertised price, or from a pharmacy appearing in a registry.
Ask the prescriber and pharmacist to explain the patient-specific rationale and the legal pathway they rely on. For legal advice about a particular prescription or facility, consult qualified counsel or the relevant regulator.
FDA's April 30, 2026 proposal concerns the 503B bulk drug substances list and is not yet a final rule.
Track sourced regulatory updates at our safety center or read the dedicated 503B proposal guide.
Your 4 Options as a Former Compounded Semaglutide Patient
If you were relying on compounded semaglutide, you have four realistic paths forward. Here is a quick comparison before we detail each:
| Option | Monthly Cost | Availability | Best For |
|---|---|---|---|
| Compounded tirzepatide | $149 to $299/mo advertised | Tirzepatide shortage resolved; any compounding requires case-specific review | Patients whose prescriber identifies an appropriate formulation and lawful pathway |
| Brand Wegovy + savings card | $0 to $650/mo | Widely available with insurance | Patients with commercial insurance covering GLP-1 |
| NovoCare patient assistance | $0 | Income-based eligibility | Patients at ≤400% federal poverty level |
| Foundayo (oral GLP-1 pill) | $149-$349/mo (dose/refill terms) | Prescription required | Patients who prefer pills over injections |
Option 1: Discuss Compounded Tirzepatide With Your Prescriber
FDA resolved the tirzepatide shortage on October 2, 2024, and shortage-based enforcement discretion ended in early 2025.
Services still advertise compounded tirzepatide, but availability through a licensed pharmacy does not establish that a particular preparation meets every 503A or 503B and state-law condition.
The SURMOUNT-1 trial studied Eli Lilly's branded tirzepatide product; its weight-loss results do not establish the effectiveness of a compounded formulation.
Compare advertised compounded tirzepatide plans by formulation, dose and recurring total, not just a first-month offer. Confirm the medication, consultation, shipping and any required fees before paying:
| Provider | Monthly Cost | Our Rating | Key Strength |
|---|---|---|---|
| EverPrime compounded tirzepatide plans | Confirm total commitment and billing schedule | 9.4/10 | Plan-dependent terms; prescription requires clinician review |
| Shed | $299/mo | 7.9/10 | 2-3 day shipping, clean app |
| Sprout Health (2025 FDA warning for misleading compounded-drug marketing) | $199 every 4 weeks | 7.8/10, active alerts: FDA warning, delivery complaints | Compounded tirzepatide shortest plan; annual option is $1,788 upfront ($149/month equivalent). Review reputation evidence |
| Direct Meds (2025 FDA warning for misleading compounded-drug marketing) | $399/mo | 7.5/10, active alert: FDA warning | Published tirzepatide injection tier; check whether your order renews and the cancellation cutoff in the terms |
For a full comparison, see our compounded tirzepatide guide and cheapest tirzepatide rankings.
Before paying any provider, ask for the dispensing pharmacy's legal name, check the applicable state license or 503B registration and inspection record, and confirm the exact formulation and concentration.
We do not certify 503A/503B compliance.
The tirzepatide shortage was already resolved in October 2024. Do not prepay or stockpile based on an urgency claim that the shortage is still active.
Regulatory status and provider terms can change; review current primary sources and our safety center before each renewal.
Option 2: Brand-Name Wegovy with Manufacturer Savings
Brand Wegovy (semaglutide 2.4mg weekly injection) is FDA-approved and widely available through telehealth providers and traditional pharmacies.
The list price is approximately $1,349/month, but several programs significantly reduce that cost:
- •Wegovy Savings Card, If you have commercial insurance that covers Wegovy, the Novo Nordisk savings card reduces your copay to as low as $0/month for the first month and up to $500/month savings. Cannot be used with Medicare, Medicaid, or any government insurance.
- •NovoCare Patient Assistance Program, Free Wegovy for patients at or below 400% of the federal poverty level (approximately $60,000/year for a single person in 2026). Apply at novonordisk-us.com. Income and residency verification required.
- •GoodRx coupons, Reduce out-of-pocket Wegovy cost to $800 to $950/month without insurance. Not ideal long-term, but useful as a bridge while pursuing insurance coverage.
- •Telehealth providers with insurance verification, Several providers in our rankings will verify your insurance coverage and help with prior authorization appeals if you are denied.
If you had insurance coverage for compounded semaglutide through a telehealth provider, note that coverage for brand Wegovy often requires a separate prior authorization.
Our insurance lookup tool can help you check your plan's GLP-1 coverage status.
Option 3: Foundayo (Oral Orforglipron), The Pill Alternative
Foundayo (orforglipron) is a newly FDA-approved oral GLP-1 receptor agonist that was approved for chronic weight management in early 2026.
Unlike injectable semaglutide or tirzepatide, it is taken once daily as a pill, no compounding, no injections, standard pharmacy dispensing.
- •Phase 3 trial results: In ATTAIN-1, the highest trial dose (36 mg) produced an 11.2% average weight reduction at week 72, against 2.1% on placebo. These results describe adults with obesity without diabetes under the treatment-regimen estimand, not a direct comparison with injectable semaglutide or tirzepatide. The trial strength refers to a study formulation, not a commercial tablet dosing instruction.
- •Cost: $649/month list price; LillyDirect self-pay runs $149 to $349/month depending on dose and refill timing (checked September 20, 2026)
- •Key advantage: Oral route, no cold storage required, available at standard retail pharmacies
- •Evidence limit: Results from separate trials do not establish a head-to-head efficacy ranking against injections.
Read the full analysis in our Foundayo price and dose page and our Foundayo vs Wegovy pill comparison.
The ATTAIN-1 and Wegovy 25 mg weight-management results come from separate placebo-controlled trials; those averages are not a head-to-head comparison or a prediction of your result.
Option 4: Appeal Your Insurance Denial
If your insurer previously denied GLP-1 coverage, that has changed. As of 2026, most major commercial insurers cover at least one GLP-1 medication for obesity when medical necessity is documented. A strong appeal should include:
- •BMI documentation, A BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (Type 2 diabetes, hypertension, obstructive sleep apnea, cardiovascular disease)
- •Prior treatment documentation, Evidence of failed attempts with at least one other weight management approach
- •Letter of medical necessity, From your prescribing provider, ideally a physician or NP, documenting clinical need
- •Specific drug requested, Appeal for the specific covered GLP-1 on your formulary; use your insurer's preferred drug if one is listed
Use our insurance lookup tool to check GLP-1 coverage policies by major insurer, or our eligibility checker to see if you meet the criteria insurers typically require.
How to Choose Between Your Options
Your best path depends primarily on your insurance situation and weight loss goals:
| Your Situation | Best Option |
|---|---|
| No insurance, want the lowest cost | Gala lists compounded tirzepatide from $99/mo equivalent on an annual plan billed once a year; compare the full payment and other plans at /cheapest-tirzepatide |
| Had good results on compounded semaglutide | Ask the prescriber to reassess the exact product; branded-trial efficacy cannot be transferred to compounded options |
| Commercial insurance covering GLP-1s | Brand Wegovy or Zepbound with savings card |
| Income ≤400% federal poverty level | NovoCare patient assistance (free Wegovy) |
| Hate injections, prefer pills | Foundayo (orforglipron) $149-$349/mo by dose/refill timing |
| Medicare or Medicaid patient | Check the exact benefit: Medicare Bridge has separate eligibility; Medicaid rules depend on the state and plan |
| Previously denied by insurance | Appeal with medical necessity letter; use our insurance tool |
Not sure which provider to use? Take our 7-question match quiz, it factors in your budget, insurance status, injection preference, and health goals to recommend the best provider for your situation.
Or see all options ranked by price on our cheapest GLP-1 medication guide, or use the cost calculator to see a side-by-side price comparison.
What This Means for Semaglutide vs. Tirzepatide
Post-shortage enforcement has led some telehealth services to promote tirzepatide instead. That commercial shift should not be mistaken for an efficacy conclusion.
Head-to-head and pivotal trials compare specific FDA-approved branded products; they do not establish outcomes for compounded formulations.
Our semaglutide vs tirzepatide comparison keeps the branded clinical evidence separate from compounded price listings.
| Factor | Compounded Semaglutide (was) | Compounded Tirzepatide (now) |
|---|---|---|
| Regulatory context | Semaglutide shortage resolved Feb 2025; case-specific 503A/503B analysis | Tirzepatide shortage resolved Oct 2024; case-specific 503A/503B analysis |
| Clinical weight loss | Not established for a compounded product; STEP 1 studied branded Wegovy | Not established for a compounded product; SURMOUNT-1 studied branded tirzepatide |
| Lowest monthly cost | $99/mo (was) | $149/mo |
| Mechanism | GLP-1 agonist only | Dual GLP-1 + GIP agonist |
| Dosing | Weekly injection | Weekly injection |
Advertised compounded prices differ, but there is no defensible compounded-product 'weight loss ceiling' to divide into those prices. Individual reports do not substitute for product-specific trials.
If a prescriber considers a patient-specific compounded formulation, Willow advertises its GLP-1 program at $299/mo; verify the exact drug, ongoing total, dispensing pharmacy, and legal basis before enrolling.
See our brand vs compounded GLP-1 guide for the regulatory framework.
Frequently Asked Questions
Is compounded semaglutide completely illegal in 2026?
Is compounded semaglutide completely illegal in 2026?
No blanket statement covers every preparation. FDA resolved the semaglutide shortage and ended temporary shortage-based enforcement discretion in 2025.
A patient-specific 503A prescription or a 503B preparation must still satisfy all applicable federal and state conditions; FDA's 2026 503B bulk-list action remains a proposal, not a final universal ban.
Can I still get compounded semaglutide from my telehealth provider?
Can I still get compounded semaglutide from my telehealth provider?
Some telehealth providers still advertise compounded semaglutide. An advertisement does not establish that a particular prescription or batch meets section 503A or 503B and state-law conditions.
Ask for the dispensing pharmacy, exact formulation and concentration, patient-specific rationale, and current license or registration record before paying.
How do I know if tirzepatide is right for me after semaglutide?
How do I know if tirzepatide is right for me after semaglutide?
A prior response to one compounded formulation does not predict your response to another.
Tirzepatide and semaglutide have different receptor activity, labeled dosing, contraindications, and evidence bases, while compounded products add formulation and concentration uncertainty.
A prescriber should reassess your history and the exact proposed product; our eligibility checker is educational and cannot make that clinical decision.
Will compounded tirzepatide also be banned?
Will compounded tirzepatide also be banned?
No final FDA action cited here creates a simple future 'ban' answer. Tirzepatide's shortage was resolved in October 2024 and shortage-based enforcement discretion ended in early 2025.
FDA's April 30, 2026 proposal would affect the 503B bulk-list pathway if finalized, but comments closing did not finalize it.
FDA's March 3, 2026 announcement of 30 telehealth marketing letters addressed promotional claims, not a blanket product-safety finding. Check our safety center for sourced updates.
What happens to patients on Medicare who can't get compounded semaglutide?
What happens to patients on Medicare who can't get compounded semaglutide?
Medicare's basic Part D benefit excludes weight-loss-only use, while qualifying non-weight-management indications can follow plan-specific coverage rules.
The separate Bridge began July 1, 2026 and includes certain branded formulations for eligible patients, not compounded semaglutide.
Medicaid is a different program with state and plan rules. Medicare's covered products and our coverage guide explain the next steps.
Sources
- FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize, U.S. Food and Drug Administration, including the March 10 and April 28, 2025 semaglutide updates
- FDA Warning Letter, JulyMD, September 2025, U.S. Food and Drug Administration
- STEP 1 Trial, Semaglutide 2.4mg for Obesity, New England Journal of Medicine, 2021
- SURMOUNT-1 Trial, Tirzepatide for Obesity, New England Journal of Medicine, 2022
- FDA Drug Shortage Database, U.S. Food and Drug Administration
- Despite FDA Crackdown, Unapproved GLP-1s Still Threaten the Industry, Healthcare Brew, March 2026
- FDA to Restrict Ingredients Used in Mass-Marketed Compounded GLP-1s, AJMC, 2026
- FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s, U.S. Food and Drug Administration, March 3, 2026
- FDA's Focus Returns to Compounding and Telehealth: Another Wave of Warning Letters, National Law Review, June 2026
- FDA Issues Warnings to 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1 Medications, Drug Topics, June 2026
Some links pay us a commission. That never changes a score or a ranking. How we work
Medical disclaimer: This article is general information, not medical advice. Talk to a licensed clinician before you start, stop or change any medication. Prices and rules can change after the date we checked them.
Affiliate disclosure: Some links in this article are affiliate links. If you join a program through one, we may earn a commission at no extra cost to you.
Medicare & GLP-1
Medicare GLP-1 Coverage Guide
On Medicare? From July 1, 2026, the Medicare GLP-1 Bridge sets a $50 monthly copay for Wegovy, Zepbound and Foundayo. Our guide explains who qualifies and what it covers.
Read the Medicare guide →Related Reading
Keep exploring this topic
What the doctors say
Quotes from named doctors and medical bodies, each linked to where they said it. We did not ask for them, and they do not endorse any provider.
“While compounding can play an appropriate role when used to meet the specific needs of an individual patient, the large-scale production and marketing of compounded versions of these medicines raises serious safety risks when products have not undergone the rigorous scientific and regulatory review required for FDA-approved therapies.”
“It's not just filling out a form online and then having some random healthcare provider sign off on it. There are concerns with some of these online programs that there's not a proper evaluation, there's not a baseline, and there's not proper supervision.”
“Compounded drugs can be important for overcoming shortages or meeting unique patient needs, but compounders should not try to compound drugs in a way that circumvents FDA's approval process.”
Quotes are general medical commentary about GLP-1 medications, independently sourced and not solicited by GLP-1 Picks. They are not an endorsement of any provider, our provider scores are set solely by our published methodology.




